On April 30, the FDA approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17.
Read more at fda.gov.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
